05/08/2026
BPC-157 CAUSES CANCER? Then show me the evidence!
One of the most repeated arguments against BPC-157 is simple:
1- BPC-157 promotes angiogenesis.
2- Cancer uses angiogenesis.
3- Therefore, BPC-157 promotes cancer.
Except biology isn't that simple. Angiogenesis is also fundamental to healing, tissue repair and restoring blood flow. Cancer can hijack that process but angiogenesis itself is not cancer.
And here's the inconvenient part: There is currently NO human evidence demonstrating that BPC-157 causes cancer.
In fact, experimental research has reported BPC-157 inhibiting proliferation and VEGF signaling in human melanoma cells. In cancer-cachexia models, it counteracted muscle wasting, inflammation and weight loss and prolonged survival.
Does that mean BPC-157 cures cancer?: Absolutely NOT.
It means the biology is far more nuanced than the headline.
Even the FDA's 2026 evaluation found insufficient carcinogenicity data to determine BPC-157's cancer risk.
And on July 23, an FDA advisory committee voted 8–6, with one abstention, in favor of adding BPC-157 to the 503A Bulks List for compounding consideration.
Important: that is NOT FDA drug approval.
My point? Stop turning hypotheses into facts simply because they sound plausible.
BPC-157 has not been established as a cancer treatment. And current evidence has not demonstrated that it causes cancer in humans either.
Science doesn't need fear or hype. It needs better data.
